Frohlich Tom 4

What Happened
Tom Frohlich, CEO of Jade Biosciences (JBIO), was granted a total of 551,250 shares as awards on Feb 12, 2026: 78,750 shares (RSUs) and 472,500 derivative awards, all at $0. The awards are compensation grants (not open-market purchases or sales). Per the filing, the RSUs are a contingent right to receive common shares and vest over time rather than delivering immediate, free trading stock.

Key Details

• Transaction date: 2026-02-12; Form 4 filed 2026-02-13 (timely — within SEC reporting window).
• Grant amounts/prices: 78,750 shares @ $0.00 (award/RSUs) and 472,500 shares @ $0.00 (derivative award) — total 551,250 awarded.
• Vesting (footnote F1): RSUs vest 1/4 on each of the first four anniversaries of Feb 15, 2026, subject to continued service. Each RSU converts to one share upon vesting.
• Other footnotes of note: F2 notes inclusion of 1,581 shares acquired under the company ESPP in Dec 2025; F3 describes the vesting schedule for a previously disclosed option (1/4 on Feb 15, 2027, then monthly over three years).
• Shares owned after the reported grants: not specified in the excerpt provided (refer to the full Form 4 for total post-grant holdings).

Context: These awards are standard executive compensation—time-based RSUs/derivative awards that vest over years—so they do not represent an immediate market purchase or sale. They increase potential future share ownership if Frohlich remains with the company and the awards vest.